Replies to post #246507 on Biotech Values

[randychub]

Seems a bit rich given they don’t have a drug in phase 3 trials yet. If I remember correctly even you didn’t think they woold get this type of bump off of the latest glp1 results. In support I would say the offering did go well.

Does their glp1 have advantages over Rybelsus?

Thanks for your thoughts!!

[jmkobers]

Heard Fidelity took 11% share per 13-G